What is the optimal pre‑operative, intra‑operative, and post‑operative management of posterior synechiae in a patient undergoing small‑incision cataract surgery (SICS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Posterior Synechiae in Small-Incision Cataract Surgery

In patients with posterior synechiae undergoing small-incision cataract surgery, aggressive perioperative pupil dilation with mydriatic agents is essential to prevent synechiae formation, combined with extended topical corticosteroid therapy (prednisolone acetate 1% four times daily for 4-6 weeks) to minimize postoperative inflammation that drives adhesion formation. 1, 2, 3

Preoperative Management

Assessment and Risk Stratification

  • Identify pre-existing posterior synechiae through careful slit-lamp examination, as their presence increases the risk of postoperative synechiae formation by over 12-fold (OR: 12.868) 4
  • Document pupil size and reactivity, recognizing that miotic pupils represent a complex surgical feature requiring modified techniques 2
  • Perform B-scan ultrasonography to rule out posterior segment pathology that could affect surgical planning 2

Preoperative Pharmacologic Preparation

  • Initiate aggressive pupil dilation with mydriatic and cycloplegic agents to break existing synechiae and maximize pupil diameter 1, 3
  • Consider preoperative topical corticosteroids if significant inflammation is present to reduce the inflammatory substrate that promotes synechiae formation 1

Intraoperative Management

Surgical Technique Modifications

  • Use pupil expansion devices or iris hooks when miosis is present to achieve adequate surgical exposure and prevent iris trauma, which is a major risk factor for postoperative synechiae 2, 5
  • Minimize intraoperative trauma to iris tissue, as surgical trauma significantly increases synechiae risk 5
  • Perform a carefully sized anterior capsulectomy, as capsulectomy size influences posterior synechiae formation between iris and anterior capsule remnants 5
  • Ensure complete removal of viscoelastic material at surgery completion, as retained viscoelastic can promote inflammation and fibrin deposition 6

IOL Selection Considerations

  • Prefer three-piece acrylic IOLs over single-piece designs when posterior synechiae risk is elevated, as single-piece IOLs carry 2.7-fold higher odds of postoperative synechiae formation (OR: 2.658) 4
  • Target standard monofocal IOL for distance vision rather than premium IOLs, particularly if posterior segment pathology exists 2

Postoperative Management

Aggressive Anti-Inflammatory Protocol

  • Prescribe topical prednisolone acetate 1% four times daily with an extended taper over 4-6 weeks, as the American Academy of Ophthalmology emphasizes this is essential for complex cases with increased inflammation risk 1, 2
  • Add topical NSAID (ketorolac 0.45%) for the first postoperative month to reduce inflammation and cystoid macular edema risk 2
  • Intensify steroid therapy immediately if anterior chamber fibrin deposition develops, as this increases synechiae risk 6-fold (OR: 6.012) 4

Critical Pupil Management

  • Dilate the pupil regularly during follow-up to prevent synechiae formation, as the American Academy of Ophthalmology specifically recommends this intervention 1, 3
  • Use mydriatic agents (tropicamide or cyclopentolate) at least 4 times daily in the early postoperative period when synechiae risk is highest 7, 8
  • Continue mydriatic therapy for several weeks rather than the standard brief course, particularly in high-risk cases 7, 8

Monitoring Protocol

  • Examine at postoperative day 1,3,7,14, and 30 with careful slit-lamp assessment for early synechiae formation 1
  • Check IOP at each visit, as synechiae can contribute to angle closure and IOP elevation 1
  • Perform gonioscopy once corneal clarity permits to assess angle status and identify peripheral anterior synechiae 1, 6

Management of Established Synechiae

Medical Intervention

  • Intensify mydriatic therapy immediately upon detecting early synechiae formation, using agents 4-6 times daily 7, 8
  • Increase corticosteroid frequency to control the inflammatory component driving adhesion formation 7, 8

Surgical Options for Refractory Cases

  • Consider surgical lysis of synechiae (synechiolysis) if performed within 6-12 months, as this timeframe offers the best chance of successfully reopening closed structures 1
  • Perform goniosynechialysis if peripheral anterior synechiae compromise aqueous outflow and elevate IOP 1, 6

Critical Pitfalls to Avoid

  • Do not underestimate inflammation control: Inadequate or prematurely tapered corticosteroids are a primary driver of synechiae formation 5, 4
  • Do not defer pupil dilation: Failure to maintain mydriasis in the early postoperative period allows synechiae to form rapidly 1, 3
  • Do not ignore pre-existing synechiae: These dramatically increase postoperative risk and require intensified preventive measures 4
  • Do not use gas tamponade unnecessarily: If combined vitrectomy is performed, C₃F₈ gas increases synechiae risk 4-fold (OR: 4.051) compared to balanced salt solution 4
  • Do not miss anterior chamber fibrin: Early fibrin deposition requires immediate aggressive intervention to prevent permanent adhesions 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cataract Surgery Indications and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Iritis-Related Pupil Deformity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Risk factors of iris posterior synechia formation after phacovitrectomy with three-piece acrylic IOL or single-piece acrylic IOL.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2009

Guideline

Management of Rising Intraocular Pressure Following Traumatic Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is cataract extraction and intraocular lens (IOL) implant medically indicated for an older adult patient with a nuclear sclerotic cataract in the right eye, developed following a corneal ulcer, with posterior synechiae and corneal scar, and no view of the retina?
In a systemic lupus erythematosus patient receiving hydroxychloroquine (200–400 mg daily) and belimumab (10 mg/kg IV every 4 weeks) who has brief recurrent malar rash lasting only a few hours and persistently negative anti‑double‑stranded DNA antibodies, should I modify the current therapy?
Which long‑acting insulin and starting dose should I prescribe for an obese adult with an A1C of 11.7% and severe systolic hypertension but otherwise normal temperature, heart rate, renal function, and oxygen saturation?
What is the recommended management for an adult with post‑viral headache, including acute analgesia, supportive measures, and indications for prophylactic therapy?
What are the recommended dosing regimens, contraindications, and precautions for Imitrex (sumatriptan) in adults with episodic migraine?
After completing a 2‑month intensive phase of isoniazid, rifampicin, pyrazinamide, and ethambutol for tuberculous cervical lymphadenitis, what is the appropriate continuation phase regimen, dose, duration, and monitoring for a 12‑year‑old boy weighing 47 kg?
How should I manage a systemic lupus erythematosus patient on hydroxychloroquine and belimumab who has persistent fever, low complement C4, borderline complement C3, and negative anti‑double‑stranded DNA antibodies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.